Any current/future new fundraising through debt or equity?

No specific mention of new fundraising through debt or equity for the current or future periods. Net debt as of FY25 year-end was around Rs. 3,500 crore. For FY26, the company expects net debt to be lower by Rs. 200-300 crore due to cash flow unlocking from working capital and reduced CAPEX intensity. The company is comfortable managing volume-led growth in FY26 without a significant increase in absolute working capital. There are no indications of planned equity fundraising; the focus appears to be on capital discipline and leveraging existing financial resources.

Any current/future capex/capital investment/strategic investment?

FY25 CAPEX was about Rs. 1,372 crore, aligned with expectations. Major ongoing capital investment is at Zone-4, with phased commissioning scheduled through FY26. Newly operational pilot plant at Zone-4 started commercial operations, focusing on new product development and innovation. FY26 CAPEX is planned at about Rs. 950-1,000 crore. Maintenance CAPEX expected to be Rs. 150-200 crore; remaining CAPEX mainly for new initiatives at Zone-4. Zone-4 commissioning will continue in Q3 and Q4 of FY26, including the multipurpose and calcium chloride plants. Volume growth in FY26 will primarily come fr

Future growth expectations in sales/revenue/volumes?

FY25 volume growth was robust, with a 17% year-on-year increase at the portfolio level. Strong volume growth driven by Energy and non-energy businesses; Q4 volumes grew 14%-21% quarter-on-quarter. Continued focus on volume-led growth; capacity utilization indicates significant upside for volume growth from existing assets. New projects at Zone IV will contribute more materially from FY27, with limited volume impact in FY26. MMA product volumes expected to ramp up over 12-24 months, targeting full capacity utilization and market development within two years. FY26 volume growth expected to conti

Future growth expectations in earnings/operating earnings/profits/EPS?

FY ’26 expected to continue volume-led growth driven by better utilization of existing capacities and new initiatives. EBITDA guidance for FY ’28 projected between Rs. 1,800 crore to Rs. 2,200 crore. PAT for FY ’28 estimated around Rs. 900 crore to Rs. 1,000 crore at the lower end of EBITDA, and Rs. 1,200 crore to Rs. 1,300 crore at the higher end. Ongoing heavy CAPEX cycle will keep depreciation high; maintenance CAPEX around Rs. 150-200 crore with remaining focused on new product initiatives (Zone-4). Cost optimization initiatives largely to materialize in FY ’27; partial benefits expected i

Aarti Industries LtdQ1 FY26Chemicals & Petrochemicals

Aarti Industries Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹535P/E: 33.8Market Cap: ₹17.6K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→FY25 volume growth was robust, with a 17% year-on-year increase at the portfolio level.
→Strong volume growth driven by Energy and non-energy businesses; Q4 volumes grew 14%-21% quarter-on-quarter.
→Continued focus on volume-led growth; capacity utilization indicates significant upside for volume growth from existing assets.
→New projects at Zone IV will contribute more materially from FY27, with limited volume impact in FY26.
→MMA product volumes expected to ramp up over 12-24 months, targeting full capacity utilization and market development within two years.
→FY26 volume growth expected to continue but precise quarter-on-quarter predictions are uncertain due to external factors like tariffs and geopolitical risks.
→Management remains optimistic about sustaining volume growth and achieving strategic three-year EBITDA targets.

Margin guidance

Category 3

→FY ’26 expected to continue volume-led growth driven by better utilization of existing capacities and new initiatives.
→EBITDA guidance for FY ’28 projected between Rs. 1,800 crore to Rs. 2,200 crore.
→PAT for FY ’28 estimated around Rs. 900 crore to Rs. 1,000 crore at the lower end of EBITDA, and Rs. 1,200 crore to Rs. 1,300 crore at the higher end.
→Ongoing heavy CAPEX cycle will keep depreciation high; maintenance CAPEX around Rs. 150-200 crore with remaining focused on new product initiatives (Zone-4).
→Cost optimization initiatives largely to materialize in FY ’27; partial benefits expected in FY ’26.
→Volume growth focus remains strong, with expectation to increase capacity utilization over next 1-2 years.
→Net debt expected to peak and then reduce by Rs. 200-300 crore in FY ’26 due to cash flow improvements and lower CAPEX intensity.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of new fundraising through debt or equity for the current or future periods.
→Net debt as of FY25 year-end was around Rs. 3,500 crore.
→For FY26, the company expects net debt to be lower by Rs. 200-300 crore due to cash flow unlocking from working capital and reduced CAPEX intensity.
→The company is comfortable managing volume-led growth in FY26 without a significant increase in absolute working capital.
→There are no indications of planned equity fundraising; the focus appears to be on capital discipline and leveraging existing financial resources.

Order book

The provided transcript from the Q4 FY25 earnings call does not explicitly mention the current or expected order book or pending orders in specific terms. However, related insights include: - The company is focused on volume-led growth with increasing utilization of existing capacities. - Long-term contracts such as 20-year nitric acid purchase agreements are performing as expected. - New contracts with global majors, including specialty polymer intermediates, are ramping up. - The company is actively developing new product markets (e.g., MMA) and expanding customer and geographic bases. - Growth initiatives, including CAPEX projects at Zone-4, are ongoing to support new product developments. - Market development and contract performance indicate a healthy pipeline aligned with the company’s three-year growth strategy. No specific numbers or orderbook size details were disclosed in the transcript.

Capex plans

Yes

→FY25 CAPEX was about Rs. 1,372 crore, aligned with expectations.
→Major ongoing capital investment is at Zone-4, with phased commissioning scheduled through FY26.
→Newly operational pilot plant at Zone-4 started commercial operations, focusing on new product development and innovation.
→FY26 CAPEX is planned at about Rs. 950-1,000 crore.
→Maintenance CAPEX expected to be Rs. 150-200 crore; remaining CAPEX mainly for new initiatives at Zone-4.
→Zone-4 commissioning will continue in Q3 and Q4 of FY26, including the multipurpose and calcium chloride plants.
→Volume growth in FY26 will primarily come from better utilization of existing capacities; new Zone-4 projects expected to ramp up post-FY26.
→Cost optimization and hybrid power projects initiated, with major benefits expected from FY27 onwards.

How does Aarti Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Aarti Industries Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Aarti Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio